Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Peel Hunt

Peel Hunt reaffirmed their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report issued on Monday morning.

A number of other analysts have also recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on Hikma Pharmaceuticals from GBX 1,900 ($24.83) to GBX 1,800 ($23.52) and set a neutral rating for the company in a research report on Wednesday, January 2nd. Barclays reiterated an equal weight rating and issued a GBX 1,950 ($25.48) price target on shares of Hikma Pharmaceuticals in a research note on Friday, November 9th. Jefferies Financial Group raised Hikma Pharmaceuticals to a buy rating and raised their price objective for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a report on Tuesday, November 27th. Finally, Citigroup reissued a buy rating and set a GBX 2,250 ($29.40) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, October 30th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of GBX 1,801.43 ($23.54).

LON:HIK opened at GBX 1,595 ($20.84) on Monday. Hikma Pharmaceuticals has a 52-week low of GBX 814.20 ($10.64) and a 52-week high of GBX 2,346 ($30.65).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Further Reading: Market Capitalization and Individual Investors

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply